213 related articles for article (PubMed ID: 11313480)
21. Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia.
Liu Q; Schwaller J; Kutok J; Cain D; Aster JC; Williams IR; Gilliland DG
EMBO J; 2000 Apr; 19(8):1827-38. PubMed ID: 10775267
[TBL] [Abstract][Full Text] [Related]
22. Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor.
Bousquet C; Susini C; Melmed S
J Clin Invest; 1999 Nov; 104(9):1277-85. PubMed ID: 10545526
[TBL] [Abstract][Full Text] [Related]
23. TEL-JAK2 mediates constitutive activation of the phosphatidylinositol 3'-kinase/protein kinase B signaling pathway.
Nguyen MH; Ho JM; Beattie BK; Barber DL
J Biol Chem; 2001 Aug; 276(35):32704-13. PubMed ID: 11435425
[TBL] [Abstract][Full Text] [Related]
24. The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation.
Iwamoto T; Senga T; Naito Y; Matsuda S; Miyake Y; Yoshimura A; Hamaguchi M
Oncogene; 2000 Sep; 19(41):4795-801. PubMed ID: 11032030
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-3-induced activation of the JAK/STAT pathway is prolonged by proteasome inhibitors.
Callus BA; Mathey-Prevot B
Blood; 1998 May; 91(9):3182-92. PubMed ID: 9558373
[TBL] [Abstract][Full Text] [Related]
26. Activation of the NF-kappaB pathway by the leukemogenic TEL-Jak2 and TEL-Abl fusion proteins leads to the accumulation of antiapoptotic IAP proteins and involves IKKalpha.
Malinge S; Monni R; Bernard O; Penard-Lacronique V
Oncogene; 2006 Jun; 25(25):3589-97. PubMed ID: 16434962
[TBL] [Abstract][Full Text] [Related]
27. Distinct activities of suppressor of cytokine signaling (SOCS) proteins and involvement of the SOCS box in controlling G-CSF signaling.
van de Geijn GJ; Gits J; Touw IP
J Leukoc Biol; 2004 Jul; 76(1):237-44. PubMed ID: 15107455
[TBL] [Abstract][Full Text] [Related]
28. TEL-Syk fusion constitutively activates PI3-K/Akt, MAPK and JAK2-independent STAT5 signal pathways.
Kanie T; Abe A; Matsuda T; Kuno Y; Towatari M; Yamamoto T; Saito H; Emi N; Naoe T
Leukemia; 2004 Mar; 18(3):548-55. PubMed ID: 14749700
[TBL] [Abstract][Full Text] [Related]
29. v-Abl signaling disrupts SOCS-1 function in transformed pre-B cells.
Limnander A; Danial NN; Rothman PB
Mol Cell; 2004 Aug; 15(3):329-41. PubMed ID: 15304214
[TBL] [Abstract][Full Text] [Related]
30. SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling.
Haan S; Wüller S; Kaczor J; Rolvering C; Nöcker T; Behrmann I; Haan C
Oncogene; 2009 Aug; 28(34):3069-80. PubMed ID: 19543316
[TBL] [Abstract][Full Text] [Related]
31. Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2.
Leung KC; Doyle N; Ballesteros M; Sjogren K; Watts CK; Low TH; Leong GM; Ross RJ; Ho KK
Proc Natl Acad Sci U S A; 2003 Feb; 100(3):1016-21. PubMed ID: 12552091
[TBL] [Abstract][Full Text] [Related]
32. The TEL/PDGFbetaR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways.
Sternberg DW; Tomasson MH; Carroll M; Curley DP; Barker G; Caprio M; Wilbanks A; Kazlauskas A; Gilliland DG
Blood; 2001 Dec; 98(12):3390-7. PubMed ID: 11719379
[TBL] [Abstract][Full Text] [Related]
33. JAK/STAT signal transduction: regulators and implication in hematological malignancies.
Valentino L; Pierre J
Biochem Pharmacol; 2006 Mar; 71(6):713-21. PubMed ID: 16426581
[TBL] [Abstract][Full Text] [Related]
34. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines.
Okuda K; Golub TR; Gilliland DG; Griffin JD
Oncogene; 1996 Sep; 13(6):1147-52. PubMed ID: 8808688
[TBL] [Abstract][Full Text] [Related]
35. Suppressor of cytokine signaling-1 selectively inhibits LPS-induced IL-6 production by regulating JAK-STAT.
Kimura A; Naka T; Muta T; Takeuchi O; Akira S; Kawase I; Kishimoto T
Proc Natl Acad Sci U S A; 2005 Nov; 102(47):17089-94. PubMed ID: 16287972
[TBL] [Abstract][Full Text] [Related]
36. Mechanism of inhibition of growth hormone receptor signaling by suppressor of cytokine signaling proteins.
Hansen JA; Lindberg K; Hilton DJ; Nielsen JH; Billestrup N
Mol Endocrinol; 1999 Nov; 13(11):1832-43. PubMed ID: 10551777
[TBL] [Abstract][Full Text] [Related]
37. TEL/platelet-derived growth factor receptor beta activates phosphatidylinositol 3 (PI3) kinase and requires PI3 kinase to regulate the cell cycle.
Dierov J; Xu Q; Dierova R; Carroll M
Blood; 2002 Mar; 99(5):1758-65. PubMed ID: 11861293
[TBL] [Abstract][Full Text] [Related]
38. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line.
Melzner I; Bucur AJ; Brüderlein S; Dorsch K; Hasel C; Barth TF; Leithäuser F; Möller P
Blood; 2005 Mar; 105(6):2535-42. PubMed ID: 15572583
[TBL] [Abstract][Full Text] [Related]
39. Termination of growth hormone pulse-induced STAT5b signaling.
Gebert CA; Park SH; Waxman DJ
Mol Endocrinol; 1999 Jan; 13(1):38-56. PubMed ID: 9892011
[TBL] [Abstract][Full Text] [Related]
40. Evidence for a role of NF-kappaB in the survival of hematopoietic cells mediated by interleukin 3 and the oncogenic TEL/platelet-derived growth factor receptor beta fusion protein.
Besançon F; Atfi A; Gespach C; Cayre YE; Bourgeade MF
Proc Natl Acad Sci U S A; 1998 Jul; 95(14):8081-6. PubMed ID: 9653143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
